Abbott Laboratories (ABT) Stock Price

Abbott Laboratories Price

🇺🇸NYSE·CLOSED
88.79USD
Market closed
Today +/-
Today %

Abbott Laboratories (ABT) Stock | ISIN US0028241000 | WKN 850103. The current Abbott Laboratories stock price is 88.79 USD (2026). Revenue is 48.27 B USD. Net income is 10.04 B USD. The P/E ratio is 15.46. Market capitalization is 155.2 B USD. Abbott Laboratories operates in the Health sector.

Over the last 19 years Abbott Laboratories grew revenue by 3.6% annually, reaching 44.33 B USD. Earnings per share have grown at 6.6% per year over the last 19 years. For Abbott Laboratories, the net margin of 14.7% is down versus 16.4% a few years ago. At today's price the dividend yield works out to roughly 2.66%. The payout ratio is around 49% of earnings. The dividend has grown at 3.8% per year over the past 19 years.

Abbott Laboratories stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Abbott Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Abbott Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Abbott Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Abbott Laboratories Stock Price History
DateAbbott Laboratories Price
Access this data via the Eulerpool API

Abbott Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
22.48 B USD
4.06 B USD
1.72 B USD
Jan 1, 2007
25.91 B USD
4.58 B USD
3.61 B USD
Jan 1, 2008
29.53 B USD
5.83 B USD
4.88 B USD
Jan 1, 2009
30.77 B USD
6.61 B USD
5.75 B USD
Jan 1, 2010
35.17 B USD
6.46 B USD
4.63 B USD
Jan 1, 2011
21.41 B USD
1.59 B USD
4.73 B USD
Jan 1, 2012
19.05 B USD
1.36 B USD
5.96 B USD
Jan 1, 2013
19.66 B USD
2.13 B USD
2.58 B USD
Jan 1, 2014
20.25 B USD
2.76 B USD
2.28 B USD
Jan 1, 2015
20.41 B USD
2.96 B USD
4.42 B USD
Jan 1, 2016
20.85 B USD
3.06 B USD
1.4 B USD
Jan 1, 2017
27.39 B USD
1.87 B USD
477 M USD
Jan 1, 2018
30.58 B USD
3.73 B USD
2.37 B USD
Jan 1, 2019
31.9 B USD
4.67 B USD
3.69 B USD
Jan 1, 2020
34.61 B USD
5.43 B USD
4.5 B USD

Abbott Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 19, 2026, 5:04 AM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (B USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
202420252026e2027e2028e2029e2030e2031e
41.9544.3348.2751.8455.4859.1863.4767.63
4.595.678.97.397.026.677.256.55
55.5656.6652.0348.4545.2742.4439.5737.14
23.3125.1225.1225.1225.1225.1225.1225.12
13.46.5210.0411.0412.0912.9814.7516.07
134.18-51.3253.899.999.57.3413.678.89
2.22.362.523.063.37---
7.847.276.7821.4310.13
1.751.751.751.751.751.751.751.75
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Abbott Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Abbott Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Abbott Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Abbott Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Abbott Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Abbott Laboratories stock margins

The Abbott Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Abbott Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Abbott Laboratories.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
56.33 %
18.05 %
7.64 %
Jan 1, 2007
55.92 %
17.67 %
13.92 %
Jan 1, 2008
57.29 %
19.73 %
16.53 %
Jan 1, 2009
57.06 %
21.48 %
18.68 %
Jan 1, 2010
58.3 %
18.36 %
13.15 %
Jan 1, 2011
53 %
7.4 %
22.09 %
Jan 1, 2012
53.29 %
7.14 %
31.3 %
Jan 1, 2013
53.23 %
10.85 %
13.1 %
Jan 1, 2014
54.57 %
13.65 %
11.28 %
Jan 1, 2015
57.22 %
14.52 %
21.68 %
Jan 1, 2016
56.43 %
14.66 %
6.71 %
Jan 1, 2017
54.74 %
6.83 %
1.74 %
Jan 1, 2018
58.5 %
12.2 %
7.74 %
Jan 1, 2019
58.64 %
14.64 %
11.56 %
Jan 1, 2020
56.75 %
15.69 %
12.99 %

Abbott Laboratories Stock Revenue, EBIT, Earnings per Share

The Abbott Laboratories earnings per share therefore indicates how much revenue Abbott Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
14.62 USD
2.64 USD
1.12 USD
Jan 1, 2007
16.61 USD
2.94 USD
2.31 USD
Jan 1, 2008
18.92 USD
3.73 USD
3.13 USD
Jan 1, 2009
19.78 USD
4.25 USD
3.7 USD
Jan 1, 2010
22.6 USD
4.15 USD
2.97 USD
Jan 1, 2011
13.66 USD
1.01 USD
3.02 USD
Jan 1, 2012
11.97 USD
0.85 USD
3.75 USD
Jan 1, 2013
12.49 USD
1.36 USD
1.64 USD
Jan 1, 2014
13.26 USD
1.81 USD
1.5 USD
Jan 1, 2015
13.55 USD
1.97 USD
2.94 USD
Jan 1, 2016
14.06 USD
2.06 USD
0.94 USD
Jan 1, 2017
15.66 USD
1.07 USD
0.27 USD
Jan 1, 2018
17.28 USD
2.11 USD
1.34 USD
Jan 1, 2019
17.91 USD
2.62 USD
2.07 USD
Jan 1, 2020
19.38 USD
3.04 USD
2.52 USD

Abbott Laboratories business model & stock analysis

Abbott Laboratories is one of the largest companies in the healthcare industry worldwide. The company was founded in 1888 by Dr. Wallace C. Abbott, who aimed to develop innovative and high-quality medical products that would improve people's lives and treat illnesses. Abbott Laboratories' business model is based on the discovery, development, manufacturing, and marketing of healthcare products. These range from pharmaceuticals to diagnostic devices. The company operates in various areas, including pharmaceuticals, nutrition, diagnostics, medical technology, and animal health. In the pharmaceutical field, Abbott Laboratories is a leading provider of generic drugs as well as innovative medications specialized in treating conditions such as Parkinson's disease, cancer, or hypertension. The company is particularly known for developing medications focused on the medical needs of women, such as hormone replacement therapy or birth control pills. In the nutrition field, Abbott Laboratories leads in the development of food and supplements for specific target groups, such as premature infants, cancer patients, or those with digestive problems. Best-selling products include Similac baby formula and Ensure, a nutritional supplement for older adults. In the diagnostics field, Abbott Laboratories develops and manufactures medical diagnostic devices and systems for patient monitoring. This includes blood glucose meters, blood pressure monitors, test strips, and laboratory systems for diagnosing diseases such as diabetes, HIV, or hepatitis. Abbott Laboratories is also a significant player in the medical technology field. The company produces and distributes medical devices such as pacemakers, stents, or artificial joints. These are typically used by doctors and hospitals to optimize patient treatment. In the animal health field, Abbott Laboratories offers a wide range of products and services for agricultural farms and veterinarians. This includes animal medications, pet food, diagnostics, and other services aimed at maintaining the health and well-being of livestock. Over the years, Abbott Laboratories has received numerous awards for its products and achievements. The company is committed to improving the quality of life for people worldwide and contributes to optimizing healthcare. Abbott Laboratories is among the top 15 leading pharmaceutical and healthcare companies worldwide and currently employs around 103,000 people in over 160 countries.

Abbott Laboratories SWOT Analysis

Strengths

Abbott Laboratories possesses several key strengths that contribute to its success in the healthcare industry. These include:

  • Strong Market Presence: As a well-established global healthcare company, Abbott Laboratories has a wide market reach and a strong brand reputation.
  • Diversified Product Portfolio: With a diverse range of healthcare products, including pharmaceuticals, diagnostics, medical devices, and nutrition, Abbott Laboratories reduces its dependence on a single product or market segment.
  • Innovation and R&D Capabilities: The company invests significantly in research and development to drive innovation and maintain a competitive edge in introducing new products and technologies.
  • Financial Stability: Abbott Laboratories has a solid financial position, reflected in its consistent revenue growth and strong profitability, allowing the company to invest in expansion and acquisitions.

Weaknesses

Despite its strengths, Abbott Laboratories is also faced with certain weaknesses that could hinder its performance. These weaknesses include:

  • Product Recalls and Quality Control Issues: The company has experienced occasional product recalls and quality control challenges, which can damage its reputation and consumer trust.
  • Dependence on Third-Party Suppliers: Abbott Laboratories relies on a network of suppliers for raw materials and components, making it vulnerable to potential disruptions, such as supply chain issues or changes in supplier relationships.
  • Regulatory Challenges: Operating in a highly regulated industry, Abbott Laboratories faces compliance challenges and increased scrutiny from regulatory authorities, which could impact its operations and product approvals.

Opportunities

Abbott Laboratories can explore various opportunities to further enhance its market position and growth potential, such as:

  • Emerging Markets: Expanding into emerging markets, where there is a growing demand for healthcare products and services, presents significant opportunities for Abbott Laboratories to increase its customer base.
  • Technological Advancements: Investing in advanced technologies and digital health solutions can help Abbott Laboratories stay ahead in the evolving healthcare landscape and provide innovative solutions to meet changing customer needs.
  • Aging Population and Chronic Diseases: With the global rise in aging population and prevalence of chronic diseases, the demand for Abbott Laboratories' healthcare products and solutions is likely to increase, creating new market opportunities.

Threats

Abbott Laboratories needs to be aware of the following threats that could potentially impact its business negatively:

  • Intense Competition: The healthcare industry is highly competitive, with numerous local and global players. Abbott Laboratories faces the risk of losing market share to competitors who offer similar healthcare products and solutions.
  • Regulatory and Legal Risks: Compliance with rigorous regulations and potential legal challenges, including product liability claims, pose threats to Abbott Laboratories, requiring proactive risk management and legal expertise.
  • Increasing Healthcare Costs: As healthcare costs continue to rise, governments and healthcare providers may exert pressure to reduce pricing, which could impact Abbott Laboratories' profitability.

Abbott Laboratories Eulerpool Fair Value

Abbott Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Abbott Laboratories annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Abbott Laboratories shares outstanding

The number of shares was Abbott Laboratories in 2025 — This indicates how many shares 1.748 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
1.54 B base_Shares
Jan 1, 2007
1.56 B base_Shares
Jan 1, 2008
1.56 B base_Shares
Jan 1, 2009
1.56 B base_Shares
Jan 1, 2010
1.56 B base_Shares
Jan 1, 2011
1.57 B base_Shares
Jan 1, 2012
1.59 B base_Shares
Jan 1, 2013
1.57 B base_Shares
Jan 1, 2014
1.53 B base_Shares
Jan 1, 2015
1.51 B base_Shares
Jan 1, 2016
1.48 B base_Shares
Jan 1, 2017
1.75 B base_Shares
Jan 1, 2018
1.77 B base_Shares
Jan 1, 2019
1.78 B base_Shares
Jan 1, 2020
1.79 B base_Shares

Abbott Laboratories Dividend History

37 years of dividend payments · 5 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.26USDYTD
Jan 15, 20260.63USD 6.8%1/2
Apr 15, 20260.63USD 0.0%2/2
20252.36USD 7.3%
Jan 15, 20250.59USD 7.3%1/4
Apr 15, 20250.59USD 0.0%2/4
Jul 15, 20250.59USD 0.0%3/4
Oct 15, 20250.59USD 0.0%4/4
20242.2USD 7.8%
20232.04USD 8.5%
20221.88USD 4.4%
20211.8USD 25.0%
20201.44USD 10.0%
20191.6USD 42.9%
20181.12USD 15.5%
20171.33USD 27.4%

Abbott Laboratories dividend history and estimates

In 2025, Abbott Laboratories paid a dividend amounting to 2.36 USD. Dividend means that Abbott Laboratories distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
1.16 USD
0 USD
Jan 1, 2007
1.27 USD
0 USD
Jan 1, 2008
1.4 USD
0 USD
Jan 1, 2009
1.56 USD
0 USD
Jan 1, 2010
1.72 USD
0 USD
Jan 1, 2011
1.88 USD
0 USD
Jan 1, 2012
2.01 USD
0 USD
Jan 1, 2013
0.7 USD
0 USD
Jan 1, 2014
1.1 USD
0 USD
Jan 1, 2015
0.96 USD
0 USD
Jan 1, 2016
1.04 USD
0 USD
Jan 1, 2017
1.33 USD
0 USD
Jan 1, 2018
1.12 USD
0 USD
Jan 1, 2019
1.6 USD
0 USD
Jan 1, 2020
1.44 USD
0 USD

Abbott Laboratories dividend payout ratio

In 2025, Abbott Laboratories had a payout ratio of 48.63%. The payout ratio indicates the percentage of the company's profits that Abbott Laboratories distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
103.57 %
Jan 1, 2007
54.98 %
Jan 1, 2008
45.03 %
Jan 1, 2009
42.28 %
Jan 1, 2010
57.91 %
Jan 1, 2011
62.46 %
Jan 1, 2012
53.74 %
Jan 1, 2013
42.94 %
Jan 1, 2014
73.83 %
Jan 1, 2015
32.76 %
Jan 1, 2016
110.64 %
Jan 1, 2017
490.74 %
Jan 1, 2018
84.21 %
Jan 1, 2019
77.29 %
Jan 1, 2020
57.14 %
Price targets and forecasts for Abbott Laboratories are not yet available.

Abbott Laboratories Earnings Estimates

Abbott Laboratories Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/14/20261.16USD11.1 BUSD2026 Q1
1/22/20261.51USD11.92 BUSD2025 Q4
1/20/20261.51USD11.92 BUSD2025 Q4
4/17/20241.05USD9.91 BUSD2024 Q1
1/23/20241.2USD10.28 BUSD2023 Q4
7/18/20231.1USD9.99 BUSD2023 Q2
4/18/20231.01USD9.55 BUSD2023 Q1
1/24/20230.92USD9.78 BUSD2022 Q4
10/19/20220.95USD9.82 BUSD2022 Q3
7/20/20221.14USD10.47 BUSD2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Abbott Laboratories stock

80/100
75
Environment
82
Social
82
Governance
E

Environment

20
Scope 1 - Direct Emissions510,000
Scope 2 - Indirect emissions from purchased energy471,000
Scope 3 - Indirect emissions within the value chain10,665,000
Total CO₂ emissions981,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees46
Percentage of women in management
Percentage of Asian employees20.2
Share of Asian management20.7
Percentage of Hispanic/Latino employees11.6
Hispano/Latino Management share7.2
Percentage of Black employees9.2
Black Management Share4.6
Percentage of white employees56
White Management Share64.9
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Abbott Laboratories shareholder structure

% Name
9.99626%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.31068%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.56829%
State Street Investment Management (US)
State Street Investment Management (US)
3.61725%
Capital International Investors
Capital International Investors
2.2408%
Capital Research Global Investors
Capital Research Global Investors
2.19723%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.34192%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.34066%
Wellington Management Company, LLP
Wellington Management Company, LLP
1.02329%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
0.89963%
JP Morgan Asset Management
JP Morgan Asset Management
...

Abbott Laboratories Executives and Management Board

RF

Mr. Robert Ford

(51)

Chairman of the Board, Chief Executive Officer · since 2014

Compensation22.78 M USD
PB

Mr. Philip Boudreau

(52)

Chief Financial Officer, Executive Vice President - Finance

Compensation8.23 M USD
HA

Mr. Hubert Allen

(59)

Executive Vice President, General Counsel, Secretary

Compensation7.98 M USD
LE

Ms. Lisa Earnhardt

(55)

Executive Vice President, Group President - Medical Devices

Compensation6.56 M USD
AW

Ms. Andrea Wainer

(56)

Executive Vice President - Rapid and Molecular Diagnostics

Compensation6.29 M USD

Abbott Laboratories Supply Chain

Frequently asked questions about Abbott Laboratories

Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.

All fundamentals and in-depth analysis of Abbott Laboratories

Our stock analysis for Abbott Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abbott Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.